Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 9, 2008

Cobrabio to Manufacture ViroMed Oncology Vaccine

  • Cobra Biomanufacturing will produce ViroMed’s VM206RY, a plasmid DNA treatment for tumors expressing Her2/neu. Cobrabio will manufacture ViroMed’s master cell bank and GMP-grade VM206RY for the first clinical trials, which will be held in Korea and in the U.S.

    VM206 is an anticancer vaccine targeting Her2/neu-positive breast or ovarian cancer. The compound has shown in preclinical studies to elicit an immune response to Her-2, resulting in the reduction in the growth and the recurrence rate of breast or ovarian cancer.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »